FDA
-
Sanofi gains FDA clearance for Gaucher disease pill
The approval culminates a winding development journey for Infilbray, and provides Sanofi with a new source of income ahead of Dupixent’s looming patent expiration.
By Delilah Alvarado • Nov. 19, 2026 -
With FDA nod, Regeneron brings an RNAi drug to autoimmune disease
The product of a collaboration with Alnylam, Livsayis is now Regeneron’s first marketed RNAi drug and will compete against established medicines from AstraZeneca and Argenx.
By Ben Fidler • Nov. 19, 2026 -
Trump administration
White House pulls nomination for FDA nominee Overton
The sudden end of Heidi Overton’s candidacy likely ensures a Democrat-controlled Congress will choose the FDA’s next leader — but shouldn’t disrupt the agency, analysts say.
By Jonathan Gardner • Nov. 18, 2026 -
Roche breast cancer pill cleared by FDA
Wilserdly’s U.S. approval is seen by analysts as a “key first step” in an important launch for Roche, which has claimed the drug could become its top-selling product.
By Delilah Alvarado • Updated Nov. 17, 2026 -
Summit shares fall as FDA rejects closely watched PD-1/VEGF drug
The FDA refused to overlook ivonescimab’s failure to initially extend survival in a form of lung cancer, setting back Summit’s first chance to win a U.S. approval.
By Jonathan Gardner • Nov. 16, 2026 -
Trump administration
The FDA has over 1k open jobs — and the staffing shortage is hitting pharma
The agency is still recovering from a mass staff exodus last year that left it shorthanded. Here’s what it means for the industry.
By Kelly Bilodeau • Nov. 12, 2026 -
Bayer wins FDA nod for a new kind of blood thinner
Sunharbo’s U.S. approval is the first for a “Factor XIa” inhibitor, an anticipated class of medicines seen as a possible step forward in stroke prevention.
By Jacob Bell • Nov. 9, 2026 -
Novartis reveals cancer cases possibly linked to gene therapy Zolgensma
The FDA is now investigating the risk of malignancy associated with Zolgensma and is “evaluating whether regulatory action is appropriate.”
By Jonathan Gardner • Updated Nov. 9, 2026 -
Trump administration
HHS to allow compounders to make 6 unapproved peptides
RFK Jr. has given notice that the agency won’t take enforcement action on six peptides that controversially won a contested recommendation from outside advisers to the FDA in July.
By Kristin Jensen • Oct. 29, 2026 -
Gene editing
FDA unveils guidance for ‘plug and play’ gene therapies
The plan builds on recent FDA moves to speed "personalized" treatments by offering an approval framework for therapies benefiting different subsets of patients with the same disease.
By Kristin Jensen • Oct. 28, 2026 -
Biohaven’s previously rejected rare disease drug to get fresh FDA review
U.S. regulators have accepted a new submission for Vyglxia, offering the chance at a turnaround for another rare disease medicine spurned by previous FDA leadership.
By Delilah Alvarado • Oct. 22, 2026 -
GSK, Ionis win US approval for first-of-its-kind hepatitis B drug
Hibsago is viewed as a potential “functional cure” for chronic infections and an important part of the British drugmaker’s goal of reaching £40 billion in annual revenue by 2031.
By Delilah Alvarado • Oct. 21, 2026 -
Trump administration
FDA ‘reset’ continues with new plan for reviewing rare disease drugs
A revamped regulatory framework may give investors less of a “guessing game” as they weigh chances for drug approvals, one analyst said.
By Kristin Jensen • Oct. 15, 2026 -
Bristol Myers dips on ‘confounding’ lung drug results
Only the lower of two tested doses of the idiopathic pulmonary fibrosis drug admilparant met the trial’s main objective, adding to analyst questions about the therapy’s prospects.
By Jonathan Gardner • Oct. 12, 2026 -
Vaccines
HHS launches new plan to strengthen vaccine injury research, reporting
Spearheaded by vaccine skeptic Robert F. Kennedy Jr., the initiative will involve a new NIH clinic, an updated monitoring system and reimbursements for doctors who report suspected side effects.
By Delilah Alvarado • Updated Oct. 9, 2026 -
News roundup
Lilly, Foghorn part ways; Wave’s FDA-approved plans
The pharma giant cut its partnership after a cancer drug disappointed in testing. Elsewhere, Teva and Samsung Bioepis expanded a partnership and space biotech Varda brought in $251 million.
By Gwendolyn Wu • Oct. 1, 2026 -
Trump administration
5 FDA decisions to watch in the fourth quarter of 2026
The next three months will feature anticipated decisions on a new kind of cancer immunotherapy, as well as medicines important to the futures of Roche, GSK and Gilead.
By BioPharma Dive staff • Oct. 1, 2026 -
FDA starts review of Roche’s multiple sclerosis pill
The FDA previously hadn’t ever accepted an application of a drug like fenebrutinib in two major forms of MS. But safety questions still hang over Roche’s program.
By Delilah Alvarado • Sept. 30, 2026 -
Kodiak skyrockets on positive study data for 2 eye drugs
The Phase 3 findings suggested Kodiak might have multiple threats to Regeneron’s Eylea and added more than $3 billion to the company’s market value.
By Jonathan Gardner • Sept. 28, 2026 -
Merck, Daiichi end plans to seek speedy approval of lung cancer ADC
The FDA indicated that the data generated so far wouldn’t support an accelerated clearance of “I-DXd,” a setback that erases an edge Merck and Daiichi had over multiple fast-moving competitors.
By Ben Fidler • Sept. 28, 2026 -
Grail multicancer detection test wins FDA advisers’ backing
Panel members said the first-of-a-kind blood test should not be used to replace medical guideline-recommended cancer screenings, however.
By Susan Kelly • Sept. 24, 2026 -
Trump administration
FDA nominee Overton parries vaccine questions at Senate hearing
Pressed by lawmakers on Thursday, Trump’s pick as the next FDA chief said she’d “follow the law” on key decisions and work to speed early drug research.
By Jonathan Gardner • Sept. 24, 2026 -
Xenon shares fall following depression trial pause
The occurrence of “neuropsychiatric” adverse events in testing fueled investor doubts about a drug the FDA is already reviewing for a form of epilepsy.
By Jonathan Gardner • Sept. 18, 2026 -
China competition
FDA launches pilot program to speed up early US drug research
First teased in June and formally announced Tuesday as part of “Operation Trialblazer,” the program will partner drugmakers with research institutions to more quickly bring medicines into human testing.
By Gwendolyn Wu • Sept. 15, 2026 -
Scholar Rock SMA drug approved by FDA
Projected by some analysts as a future blockbuster, Isembyld is the first “muscle-targeted” treatment for the disease and, in clinical testing, helped improve motor function in people on standard therapies.
By Ben Fidler • Sept. 14, 2026